Peggy Geluykens

发表

Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development

H. V. van Vlijmen, A. Bender, G. V. van Westen, 2011, PloS one.

Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library

Peggy Geluykens, M. Van Loock, B. Devogelaere, 2017, Antiviral research.

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

K. Hertogs, Peggy Geluykens, Inge Vereycken, 2008, Journal of Virology.

An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitors.

Peggy Geluykens, M. Van Loock, T. Ivens, 2013, Assay and drug development technologies.

A fluorescence-based high-throughput screening assay to identify HIV-1 inhibitors.

Peggy Geluykens, M. Van Loock, J. Vingerhoets, 2013, Methods in molecular biology.

From Oxetane to Thietane: Extending the Antiviral Spectrum of 2'-Spirocyclic Uridines by Substituting Oxygen with Sulfur.

J. Neefs, E. Jacoby, Peggy Geluykens, 2022, ACS medicinal chemistry letters.

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

H. V. van Vlijmen, Peggy Geluykens, M. Cummings, 2009, Proceedings of the National Academy of Sciences.

A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Peggy Geluykens, R. Bartenschlager, A. Marchand, 2021, Nature.

Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates

Gregory D. Gromowski, A. Barrett, D. Beasley, 2023, Nature.

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Dominique Schols, Kurt Hertogs, K. Hertogs, 2010, Virology.

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

I. Dorigatti, Peggy Geluykens, Doortje Borrenberghs, 2023, PLoS Comput. Biol..